Clinical trial NCT04206644: Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages
Official title: Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Systemic Sclerosis
Keywords: Systemic sclerosis
macrophage
ruxolitinib
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2019-12-20
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 18
Standard ages: ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with systemic sclerosis according to the ACR/EULAR 2013 classification criteria for systemic sclerosis

or Lupus patients according to the ACR 2019 classification criteria

or healthy donors

Brief summary: The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients

Detailed description: Systemic sclerosis is a fibrotic and inflammatory chronic autoimmune disorder with no disease modifiying drug available to date. JAK inhibitors may represent a relevant therapeutic candidate for this disease;

The primary objective of this study is to characterize the impact of Ruxolitinib (a JAK ½ inhibitor) on the prof-fibrotic properties of MDM from SSc patients in vitro.

The primary outcome will be the concentration of CCL18 evaluate by ELISA in the condition media of MDM from SSc patients pre treated or not in vitro by ruxolitinib.

The secondary objectives :

1. To characterize the impact of ruxolitinib on other pro-inflammatory or pro-fibrotic cytokines
2. To characterize the impact of ruxolitinib on membrane expression of macrophagic polarization markers of MDM from SSc patients
3. To evaluate the impact of ruxolitinib on the phenotype of MDM from healthy donors exposed in vitro to the serum of SSc patients.
4. To determine the variability of the effects of ruxolitinib on MDM of SSc patients depending on key clinical characteristics (diffuse versus limited SSc, patients with or without Interstitial Lung disease ILD)

The secondary outcomes :

1. ELISA of the following cytokine evaluated in the condition media of SSc MDM pre-treated or not with ruxolitinib : PDGFbb, IL-6, CXCL10, CXCL4
2. Membrane expression (flow cytometry) of the following markers expressed by SSc MDM pre-treated or not with ruxoltinib : CD204, CD206, CD163, CD86, CMHII, TLR4.
3. Evaluation of the same cytokines and membrane markers in MDM from HD exposed to serum media of SSc patients.
4. Variation of the effect of ruxolitinib on the primary outcome (CCL18 secreted in the condition media of MDM from SSc patients) in sub groups depending on the following characteristics :

   * Auto antibodies (anticentromere, antitopoisomerase, anti RNA polymerase III or none)
   * modified Rodnan skin score
   * Digital ulcers (current or past)
   * Pulmonary involvement (Interstitial Lung disease on CT scan)
   * Heart involvement (Pulmonary arterial hypertension on echocardiography)

Eligibility criteria: Inclusion Criteria:

* patients with systemic sclerosis according to the ACR/EULAR 2013 classification criteria for systemic sclerosis or Patients with systemic lupus according to the ACR2019 classification criteria for systemic lupus
* with informed consent for participation to the study

Exclusion Criteria:

* patients unable to consent
* patients with anemia inferior to 7g/dL

Primary outcomes:
measure: Concentration of CCL18 in the condition media of MDM from SSc patients
timeFrame: through study completion, an average of 4 year
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Rennes University Hospital
Study officials:
affiliation: Rennes University Hospital
name: Patrick JEGO
role: PRINCIPAL_INVESTIGATOR
References: